Transition Bio, Inc. — Form D/A

Transition Bio, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2023-03-07. The offering totals $50.0M, of which $39.1M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (23)

NameRoleLocation
Samuel K CohenDirectorCAMBRIDGE, MA
George K MartinDirectorCAMBRIDGE, MA
Connor K McDermottDirectorCAMBRIDGE, MA
Gregory L MillerDirectorCAMBRIDGE, MA
Al K SandrockDirectorCAMBRIDGE, MA
Kathy K YiDirectorCAMBRIDGE, MA
Tuomas L KnowlesExecutive OfficerCAMBRIDGE, MA
Martin L KulanderExecutive OfficerCAMBRIDGE, MA
Gregory L MillerExecutive OfficerCAMBRIDGE, MA
Paxton MajorDirectorAustin, TX
Tuomas KnowlesDirectorCambridge, MA
Tuomas KnowlesExecutive OfficerCambridge, MA
Kathy YiDirectorCambridge, MA
Robert WeeksDirectorCambridge, MA
George MartinDirectorCambrige, MA
George MartinExecutive OfficerCambrige, MA
Al SandrockDirectorCambridge, MA
Stephanie TorruellaExecutive OfficerCambridge, MA
Samuel CohenDirectorCambridge, MA
Preet MakkarExecutive OfficerCambridge, MA
Connor McDermottDirectorCambridge, MA
Stephanie L TorruellaExecutive OfficerCAMBRIDGE, MA
Shaan K GandhiDirectorCAMBRIDGE, MA

Other filings by this issuer (3)

FiledFormOfferingSold
2024-10-25D$21.3M$13.3M
2024-01-10D$15.0M$6.0M
2022-04-08D$30.6M$30.6M

More